AmerisourceBergen Corporation: Initiation of Coverage – Acquisition of PharmaLex & Key Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (03/23)

This is our first report on major pharmaceutical sourcing and distribution services provider, AmerisourceBergen. The company produced strong financial results in the first quarter of fiscal 2023, with revenue of approximately $63 billion, reflecting 5% year-over-year growth and adjusted EPS growth of 5%. It managed to deliver an all-around beat and continued to maintain its dominant market position. Their fundamentals remain solid as they continue to focus on providing a differentiated value pro

Hybridan Small Cap Feast 27/10/2021

Joiners Softline, the global solutions and services provider in digital transformation and cybersecurity, with its headquarters in London, has issued GDRs to the Standard Listing Segment of the Official List, and on the Moscow Exchange. The Group had a turnover of US$1.8bn for the year ended 31 March 2021, employs c.6,000 people globally, and operates in more than 50 countries across emerging markets. Primary proceeds from the Offer are expected to be around US$400m. At the $7.5 offer price. Mkt

Small Cap Feast

Calisen Group. Potential Intention to Float. Owner and manager of essential energy infrastructure assets . Consolidated FY Dec 18 revenue £162.1m and operating profit £25.4m. Raising up to £300m in primary plus partial vendor sale. The Global Sustainable Farmland Income Trust will invest in a diversified portfolio of operational farmland assets located in major agricultural markets including the United States, Europe, New Zealand, Australia and certain countries within Latin and South America.

SP Angel Healthcare Conditions

Abcam (ABC.L): Preliminary results for the year-ended June 2019 | Diaceutics PLC (DXRX.L): Half-year results for June 2019

Small Cap Feast

Voyager AIR The Company will focus on the acquisition, leasing and management of primarily widebody aircraft, with asset management services to be provided by Amedeo Limited the IPO will comprise a Placing and Offer for Subscription of Shares to raise up to approximately US$200m. Uniphar, a diversified healthcare services business with a workforce of over 2,000, is looking to join AIM. Raising EUR135m with market cap on admission of EUR309.6m, expected 17 July 2019. Roxi Music UK music streaming

Small Cap Feast

Techniplas –global producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient. FYDec17 rev $515m. Circassia Pharma (CIR.L) - specialty pharmaceutical company focused on respiratory disease transferring from the Main Market. No funds being raised. Due 4 Feb. Greenfields Petroleum (TSX-V:GNF) production focused company with operated assets in Azerbaijan seeking AIM dual li

Small Cap Breakfast

Ovoca Gold (to be renamed Ovoca Bio PLC) - RTO of IVIX, a Russian company developing a drug candidate for the treatment of female sexual dysfunctions. No monies to be raised, market cap of £8.5m, due 30 July Nucleus Financial—independent wrap platform provider . FYDec17 revs £40.36m and PBT of £5.1m. Offer TBA. Due late July. Kropz PLC-Intention to float by the emerging plant nutrient producer with an advanced stage phosphate mining project in South Africa and exploration assets in West Africa

Small Cap Breakfast

Cradle Arc—holding company of a group of companies focused on the exploration and development of precious and base metals projects in Africa. Offer raising £2.4m with market cap of £20.13m. Expected 10 Jan 2018 | Volex VLX.L—The global provider of cable assemblies is proposing to move from the main market to AIM on 19 January. £75m market cap. FYMar18E rev £241.5m and £7.19m PBT | OnTheMarket—Intention to float on AIM to raise c.£50m which will be used to fund the growth of the OnTheMarket.com p

Small Cap Breakfast

Sareum Holdings * (SAR.L) | ABCAM (ABC.L) | Wey Education (WEY.L) | H&T Group (HAT.L) | Everyman Media Group (EMAN.L) | Impax Asset Management (IPX.L) | Nichols (NICL.L) | Focusrite (TUNE.L) | Majestic Wines (WINE.L) | Science in Sport (SIS.L)

AIM Breakfast

Next Fifteen Communications (NFC.L) | Lightwave RF (LWRF.L) | Young & Co’s Brewery (YNGA.L) | Mercia Technologies ( MERC.L) | Mobile Streams (MOS.L) | Mincon Group (MCON.L) | Proactis Holdings (PHD.L) | ABCAM (ABC.L) | IDOX (IDOX.L) | Condor Gold (CNR.L)

Venture life helps the Chinese Aged, SQS gets on the Italian Job, what next for Next 15

DDDD placing, ABC acquisition, ABDP new contract win, BMK preliminary results, CYAN £1m order, EKF collaboration, EMIS contract award, FPM new exploration licences, FITB joins Jawbone, partners with Cancer Research UK and court case judgement, GFM production update, HAYT £3m secured loan note programme and contract win, LWRF preliminary results, NFC proposed placing and trading update, SQS acquisition, STAF full year results, VLG distribution deal .

LIBERUM: Aptamer* - Prelims supports growth projections

LIBERUM: Aptamer* - Initiation - Build better binders

LIBERUM: Futura Medical: The Futura's coming

Destiny Pharma plc+ (DEST, House Stock at 57p) - Primed to go

Interims in line – new forecasts for Life Sciences

Interims are in line and show strong growth from key product lines, which bodes well for future sustainable growth. Having already rebased our FY23 estimates to remove any contribution from the delayed South Bend facility, we reintroduce FY24 & FY25 forecasts to reflect the revised schedule of revenues ramping up. These show group revenues on an improving trend and EBITDA margins strengthening towards 22%. The shares trade on an FY24 EV/EBITDA multiple of sub-10x, falling to 8x in FY25. There is

Shield Therapeutics - $26.1m fundraise ($20.0m debt)/$6.1m equity)

Shield raised $26.1m through a $20m term loan facility with SWK Holdings (unconditional) and $6.1m equity placing to fund several initiatives to drive improvement in gross-to-net (GTN) prices (including new field access team), fund the working capital needs (inventories and receivables) of the US growth story and repay the $5.7m AOP Health convertible loan. The interims and Q3 update clearly show the fruits of the Viatris collaboration, with covered lives increasing 20% to 123m (vs. 100m) and st

LIBERUM: Inspiration Healthcare: Reassuring outlook, US beckons

Oxford BioDynamics+ (OBD, House Stock at 10p) - Early availability of prostate cancer test

Hybridan Small Cap Feast - 26 Sep 23

26th September 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment ob

Interim results

Belluscura has reported interims in line with our expectations and notes strong momentum across its product range, particularly the DISCOV-R, and ‘transformational' progress in its global roll-out after signing Agreements with InnoMax and McKessen.

Artificial intelligence in UK biopharma and healthcare 11/09/2023

Artificial intelligence (AI) continues to accelerate at full speed, first by imitating the workings of a human brain and now it is drawing concepts of evolution, sometimes with synthetic data, artificially manufactured for training purposes or for privacy protection, and sometimes not even with human intervention. In this note, we examine how AI is being developed and applied by the NHS and UK mid/small cap companies for the benefit of human health and wellbeing. AI in drug discovery and devel

Interims – trading in line with upgraded estimates

NIOX delivered a strong H1, driven by Clinical revenues +29% in the period. Trading is in line with the forecasts that were materially upgraded in July. Margins continue to strengthen and cash flow is following the increased profitability. Having returned £10.5m via a special dividend in September, we expect a maiden ordinary dividend to be declared at the finals in March, reflecting the strong fundamentals and highly cash generative nature of the model. We continue to view NIOX as a unique asse

Hybridan Small Cap Feast - 28 Sep 23

28th September 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment ob

Hybridan Small Cap Feast - 03 Oct 23

3rd October 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objec

NetScientific - Interim Results – solid strategic progress paves way for value inflection

NetScientific, the deep tech and life sciences VC investment group, has released interim results to June 2023 evidencing progress in the ‘core' portfolio and first asset realisations. Amongst multiple updates detailed below, across an expansive and diversified portfolio of over 20 companies, NSCI reports a Fair Value' as at 30 June 2023 of £35.5m (H1-22: £29.2m) a 21% increase compared to H1-22A. Looking at the last six months, and excluding the market value of PDS Biotech (NASDAQ:PDS - currentl